| DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. | |
MedLine Citation:
|
PMID: 12729944 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This study examined the possible association between the polymorphism in the dopamine receptor DRD4 gene and response to risperidone among 24 Israeli Jewish adolescent inpatients with first-episode schizophrenia. Response was categorically determined by a change of >40% on the Brief Psychiatric Rating Scale (BPRS). No significant association was found between the DRD4 genotype and clinical response, although carriers of <7 repeat alleles demonstrated higher response rate (10/20 vs. 0/4, P=0.11). Studies in larger groups of adolescent schizophrenia patients are warranted to clarify the possible association between DRD4 exon III repeat alleles and the response to risperidone. |
Authors:
|
Gil Zalsman; Amos Frisch; Shaul Lev-Ran; Andrés Martin; Elena Michaelovsky; Daniela Bensason; Doron Gothelf; Eitan Nahshoni; Samuel Tyano; Abraham Weizman |
Related Documents
:
|
19748074 - The role of dna copy number variation in schizophrenia. 2577274 - Strategies for linkage studies in schizophrenia. 17033634 - Plexin b3 is genetically associated with verbal performance and white matter volume in ... 15936534 - The x-box binding protein 1 (xbp1) gene is not associated with methamphetamine dependence. 21986704 - Causes and consequences of obesity: the contribution of recent twin studies. 16995614 - Sperm parasitism in ants: selection for interspecific mating and hybridization. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology Volume: 13 ISSN: 0924-977X ISO Abbreviation: Eur Neuropsychopharmacol Publication Date: 2003 May |
Date Detail:
|
Created Date: 2003-05-05 Completed Date: 2003-07-11 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9111390 Medline TA: Eur Neuropsychopharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 183-5 Citation Subset: IM |
Affiliation:
|
Adolescent Inpatient Department, Geha Mental Health Center, Rabin Medical Center, Petach Tikva 49100, Israel. zalsman@post.tau.ac.il |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Alleles Antipsychotic Agents / therapeutic use* DNA / genetics Exons / genetics* Female Gene Frequency Humans Israel Male Pharmacogenetics Pilot Projects Polymorphism, Genetic / genetics* Psychiatric Status Rating Scales Receptors, Dopamine D2 / genetics* Receptors, Dopamine D4 Risperidone / therapeutic use* Schizophrenia / drug therapy*, genetics* |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/DRD4 protein, human; 0/Receptors, Dopamine D2; 106266-06-2/Risperidone; 137750-34-6/Receptors, Dopamine D4; 9007-49-2/DNA |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride...
Next Document: Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic ...